LUND, Sweden--(BUSINESS WIRE)--Regulatory News: BioInvent International (STO:BINV) today announced that it has gained access to novel technology for making highly efficacious immune stimulatory antibodies to combat cancer. This initiative continues BioInvent’s long standing research collaborations with the University of Southampton.
